Compare · ALC vs STAA
ALC vs STAA
Side-by-side comparison of Alcon Inc. (ALC) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALC and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- ALC is the larger of the two at $34.48B, about 24.9x STAA ($1.38B).
- Over the past year, ALC is down 21.0% and STAA is up 60.5% - STAA leads by 81.5 points.
- STAA has been more active in the news (9 items in the past 4 weeks vs 1 for ALC).
- Both have 25 recent analyst ratings on file.
- Company
- Alcon Inc.
- STAAR Surgical Company
- Price
- $68.99+1.76%
- $27.77+0.13%
- Market cap
- $34.48B
- $1.38B
- 1M return
- +4.34%
- -5.32%
- 1Y return
- -20.98%
- +60.55%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 1
- 9
- Recent ratings
- 25
- 25
Alcon Inc.
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest ALC
- Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
- SEC Form SD filed by Alcon Inc.
- SEC Form 6-K filed by Alcon Inc.
- New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
- Alcon Announces Results of 2026 Annual General Meeting
- Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada
- Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
- SEC Form 6-K filed by Alcon Inc.
- Alcon Publishes Agenda for 2026 Annual General Meeting
- Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
Latest STAA
- SEC Form S-8 filed by STAAR Surgical Company
- SEC Form 4 filed by Director Wang Christopher Min Fang
- SEC Form 4 filed by Director Lebuhn Richard T.
- SEC Form 4 filed by Director Bradsher Neal C
- Director Butcher Arthur C converted options into 5,341 shares, increasing direct ownership by 127% to 9,549 units (SEC Form 4)
- SEC Form 4 filed by Director Zhou Lilian Yansheng
- STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Silverman Lou converted options into 10,683 shares, increasing direct ownership by 2,249% to 11,158 units (SEC Form 4)
- Director Jiang Wei converted options into 10,683 shares, increasing direct ownership by 16% to 77,127 units (SEC Form 4)
- Director Zhou Lilian Yansheng was granted 3,530 shares, increasing direct ownership by 77% to 8,101 units (SEC Form 4)